Immatics NV

Immatics NV: Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer. Immatics expects to provide a combined data readout on three ACTEngine studies in Q1 2021.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
Oncology
Listing
Public, USA
Market Cap
500MM - 1B
Website:
Address:
Paul-Ehrlich-Str. 15
Tübingen, 72076
Germany

Company Participants at 2020 Wall Street "On Tap"

Thomas Ulmer
Formerly with Immatics Biotechnologies GmbH, CFO
Thomas Ulmer joined Immatics Biotechnologies GmbH in April 2018 from the Merck Group, where he was Chief Financial Officer of the Allergopharma Business Unit. During his tenure with Allergopharma he was the key architect for defining and implementing the business strategy towards geographic expansion and updating the product portfolio. Thomas Ulmer began his professional career with Merck in 2004 and has held a number of roles, including Head of Business Planning & Analysis and previously Head of Planning, Forecasting & Resource Allocation for the Merck Group. During this time, he acted as a sparring partner to the Group Executive Board and helped develop and implement the new company strategy which included a major transformation. He has also been Chief Financial Officer for Australia/ New Zealand and Financial Controller for Merck’s global generics business when it was sold to Mylan and he played a leading role of the integration of the business and built up an OTC business unit in Australia for which he received the company’s innovation award. Thomas Ulmer is a Certified Practising Accountant of CPA Australia and holds an MBA of Justus-Liebig-University of Giessen.

Top 10 Holders of Immatics N.V.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Nantahala Capital Management LLC 17.49 2,514,489 0.00 13F 12/31/20
Glaxis Capital Management LLC 0.00 0 0.00 13F 12/31/20
BlackRock Institutional Trust Co. NA 0.05 7,720 0.00 13F 12/31/20
Smith Barney Asset Management 0.01 1,421 0.00 13F 12/31/20
Global Retirement Partners LLC 0.01 1,000 0.00 13F 12/31/20
Morgan Stanley Smith Barney LLC 0.01 1,000 0.00 13F 12/31/20
NFS Netfonds Financial Service GmbH 0.01 3,600 0.00 Funds 9/30/20
FNY Investment Advisers LLC 0.00 300 0.00 13F 3/31/21
RBC Capital Markets Arbitrage SA 0.00 4 0.00 13F 12/31/20
Hound Partners LLC 0.00 0 0.00 13F 12/31/20

Top 10 Holders of Immatics N.V. Warrant 2020-01.07.25 on Immatics

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Beryl Capital Management LLC 0.00 1,424,239 0.00 13F 12/31/20
Maven Investment Partners US Ltd. 0.00 50,000 0.00 13F 12/31/20
Alyeska Investment Group LP 0.00 0 0.00 13F 12/31/20
Walleye Trading LLC 0.00 0 0.00 13F 12/31/20
Bluefin Capital Management LLC 0.00 0 0.00 13F 12/31/20
Creative Planning LLC 0.00 0 0.00 13F 12/31/20
UBS Group AG (13f Subfiler) 0.00 2,260 0.00 13F 12/31/20
Castle Creek Arbitrage LLC 0.00 16,406 0.00 13F 12/31/20
Weiss Asset Management LP 0.00 21,400 0.00 13F 12/31/20
Angelo, Gordon & Co. LP 0.00 25,075 0.00 13F 12/31/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.